• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Medtronic launches in-office study of Reveal Linq heart monitor

Medtronic launches in-office study of Reveal Linq heart monitor

May 7, 2015 By Brad Perriello

Medtronic launches in-office study of Reveal Linq cardiac monitor

Medtronic (NYSE:MDT) said it’s launching a clinical trial to compare in-office implantation of its Reveal Linq cardiac monitor with hospital implantation.

The Reveal Linq device is designed to be implanted beneath the skin on the upper left side of the chest and is indicated for monitoring patients experiencing dizziness, palpitation, fainting or syncope, chest pain and cardiac arrhythmias. Billed as the world’s smallest cardiac monitor, it’s about ⅓ the size of a triple-A battery, Medtronic said, and is designed to work for 3 years using the company’s CareLink network.

The 3-month Rio 2 trial is slated to enroll 540 patients in the U.S., the company said. It’s a 2-arm, prospective, unblinded study designed to randomize patients 1:1 for either in-office or in-hospital implantation of the Reveal Linq monitor, according to a press release. Another 150 patients are expected for an "out-of-lab" observational arm of the Rio 2 study in Europe, Australia and Canada designed to evaluate moving Reveal Linq implantations out of the cath lab to other hospital areas, Medtronic said.

"Studies such as Rio 2 may enable physicians to provide their patients with even greater access to the latest diagnostic tools and therapies. In-office procedures have the potential to help patients and reduce costs to the healthcare system," Dr. John Rogers of the Scripps Clinic in La Jolla, Calif., who performed the trails 1st in-office procedure, said in prepared remarks.

The FDA cleared Reveal Linq last year. In February, the company said a real-world study of the device in cryptogenic stroke patients showed that it detected atrial fibrillation at an even greater rate than found in a prior study.

"Physicians have embraced Reveal Linq [implantable cardiac monitor] for its ease of use, and moving the insertion procedure to the office setting has the potential to improve patient access to cardiac monitoring while enhancing the overall patient experience," vice president Nina Goodheart said.

Filed Under: Cardiac Implants, News Well Tagged With: Clinical Trials, Remote Patient Monitoring

More recent news

  • Autonomix picks up key nerve ablation catheter patent
  • Affluent Medical can move to pivotal phase of artificial urinary sphincter study
  • Globus Medical announces $500M share repurchase program
  • Cook Medical warns of issue with angiographic catheter
  • Virtuoso Surgical reports first cases with robotic endoscopy system, plans FDA IDE submission

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy